EUVIMEDObjevte EUVIMED
Crossref

Embryo‐fetal safety evaluation of ondansetron in rats

Ana Carolina Casali Reis, Bárbara Campos Jorge, Suyane da Silva Moreira, Júlia Stein, Carolina Barizan Perdão, Beatriz de Matos Manoel, Arielle Cristina Arena iD

Birth Defects Research · 2023

DOI: 10.1002/bdr2.2154 ↗

At a glance

Journal article in Birth Defects Research, 2023. Written by Ana Carolina Casali Reis and 6 co-authors. Institution: Department of Structural and Functional Biology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista - UNESP, Botucatu, São Paulo, B…. Major MEDLINE topics: Antiemetics, Embryo, Mammalian, Ondansetron. Cited 1 times so far (Crossref); 41 references. Funded by: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Ondansetron is a 5HT3 receptor antagonist, used to mitigate the effects of nausea and vomiting after chemotherapy or surgery. Since nausea and vomiting are common experiences during the first trimester of pregnancy, this antiemetic has been the main drug used during this period.

Methods

To evaluate the effects of ondansetron on the embryo‐fetal development, which are still very contradictory, pregnant rats were exposed to therapeutic doses of ondansetron (1.7 or 2.5 mg/kg) daily, from gestational day (GD) 6 to 15.

Results

No clinical signs of toxicity were observed in dams during the treatment. Although the hemato‐biochemical parameters were similar among the groups, histological changes, as well as a reduction in the weight of kidney were found in the treated dams. After fetal examination, no visceral and skeletal abnormalities were observed in treated fetuses.

Conclusion

In conclusion, therapeutic doses of ondansetron have low teratogenic potential in rats. These data provide important information about the drug safety during pregnancy.

Subjects

MeSH terms (MEDLINE)

AntiemeticsEmbryo, MammalianOndansetronAnimalsFemalePregnancyRatsNauseaVomiting

Author keywords

kidneynausea and vomitingorganogenesisratssafetyteratogenicity

Substances

AntiemeticsOndansetron

Authors and institutions

  • Department of Structural and Functional Biology, Institute of Biosciences of Botucatu, Universidade Estadual Paulista - UNESP, Botucatu, São Paulo, Brazil.
  • College of Health Science, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil.
  • Center of Toxicological Assistance (CEATOX), Institute of Biosciences of Botucatu, Universidade Estadual Paulista - Botucatu (UNESP), Botucatu, São Paulo, Brazil.

ORCID profiles: Arielle Cristina Arena

Funding

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Cite

APA

Reis, A. C. C., Jorge, B. C., da Silva Moreira, S., Stein, J., Perdão, C. B., de Matos Manoel, B., & Arena, A. C. (2023). Embryo‐fetal safety evaluation of ondansetron in rats. Birth Defects Research. https://doi.org/10.1002/bdr2.2154

Vancouver

Reis ACC, Jorge BC, da Silva Moreira S, Stein J, Perdão CB, de Matos Manoel B, et al. Embryo‐fetal safety evaluation of ondansetron in rats. Birth Defects Research. 2023. doi:10.1002/bdr2.2154

BibTeX
@article{Reis2023,
  author = {Reis, Ana Carolina Casali and Jorge, Bárbara Campos and da Silva Moreira, Suyane and Stein, Júlia and Perdão, Carolina Barizan and de Matos Manoel, Beatriz and Arena, Arielle Cristina},
  title = {Embryo‐fetal safety evaluation of ondansetron in rats},
  journal = {Birth Defects Research},
  year = {2023},
  doi = {10.1002/bdr2.2154}
}
Start for free →